Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,236,574
  • Shares Outstanding, K 95,640
  • Annual Sales, $ 2,459 M
  • Annual Income, $ -881,710 K
  • 60-Month Beta 0.61
  • Price/Sales 5.50
  • Price/Cash Flow N/A
  • Price/Book 3.81
Trade BGNE with:

Options Overview Details

View History
  • Implied Volatility 53.45% ( +3.31%)
  • Historical Volatility 45.03%
  • IV Percentile 84%
  • IV Rank 66.88%
  • IV High 61.41% on 02/15/24
  • IV Low 37.39% on 11/30/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 42
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 2,960
  • Open Int (30-Day) 2,825

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.58
  • Number of Estimates 4
  • High Estimate -1.82
  • Low Estimate -3.09
  • Prior Year -3.34
  • Growth Rate Est. (year over year) +22.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.38 +0.75%
on 04/15/24
171.25 -19.18%
on 03/19/24
-31.60 (-18.59%)
since 03/15/24
3-Month
132.95 +4.10%
on 02/02/24
184.80 -25.11%
on 03/13/24
-36.81 (-21.01%)
since 01/12/24
52-Week
132.95 +4.10%
on 02/02/24
270.57 -48.85%
on 04/18/23
-125.60 (-47.58%)
since 04/14/23

Most Recent Stories

More News
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 138.40 (-2.05%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 138.40 (-2.05%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

AMGN : 265.51 (-0.66%)
ARGX : 376.26 (-0.47%)
BGNE : 138.40 (-2.05%)
CRSP : 58.72 (-3.21%)
IMVT : 30.47 (+3.82%)
7 Best Cancer Stocks to Invest in Now

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

EXEL : 22.70 (-0.48%)
GILD : 67.75 (-0.47%)
NVS : 94.41 (+0.95%)
ON : 65.64 (-1.50%)
PFE : 25.91 (+0.19%)
MDCO : 84.90 (-0.07%)
MRK : 126.19 (+0.36%)
KURA : 19.01 (-2.41%)
AZN.LN : 10,934.000 (-0.82%)
BGNE : 138.40 (-2.05%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 67.75 (-0.47%)
AMGN : 265.51 (-0.66%)
BMY : 48.51 (+0.48%)
NVS : 94.41 (+0.95%)
BGNE : 138.40 (-2.05%)
JSPR : 26.30 (-5.12%)
VIGL : 3.16 (-1.86%)
ALVR : 0.7461 (-2.71%)
RCUS : 16.29 (-1.75%)
FLACU : 9.50 (+2.48%)
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 138.40 (-2.05%)
BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 138.40 (-2.05%)
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's...

BGNE : 138.40 (-2.05%)
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib),...

BGNE : 138.40 (-2.05%)
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones....

BGNE : 138.40 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 146.82
2nd Resistance Point 144.72
1st Resistance Point 141.56
Last Price 138.40
1st Support Level 136.31
2nd Support Level 134.21
3rd Support Level 131.05

See More

52-Week High 270.57
Fibonacci 61.8% 218.00
Fibonacci 50% 201.76
Fibonacci 38.2% 185.52
Last Price 138.40
52-Week Low 132.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar